conditions, pain is most common ly treated with analgesics. Over the past decade, there have been growing concerns about the harm -abuse and addiction, as well as serious injury and deathcaused by the use of prescription and overthecounter analgesics. These concerns have emerged in parallel with the evolving under standing of the importance of pain management in medical care. We at the Food and Drug Admin istration (FDA) have been engag ing physicians, pharmacy groups, patients, and other stakeholders in an ongoing effort to strike the right balance between two impor tant goals: on the one hand, pro viding access to pain medications for those who need them, and on the other hand, managing the va riety of risks posed by analgesic drugs. Recent FDA advisory com mittee meetings and actions reflect this effort.
Acetaminophen is one of the most commonly used analgesics. In 2008, approximately 25 billion doses were sold in the United States. 1 Acetaminophen is mar keted as a singleingredient drug but can also be found in a multi tude of overthecounter combina tion products, such as cough and cold medicines, as well as in pre scription opioid-acetaminophen combination products (e.g., Vico din [Abbott] 4 An analysis of poi soncontrol data from 2003 through 2006 identified 9179 chil dren who were inadvertently ex posed to prescription opioids. The median age of the children was 2 years, and 92% of the poison ings occurred in the child's home. 5 Such data highlight the need for additional measures to limit the abuse and misuse of prescription opioids and prevent the acciden tal exposure of children.
As part of the process involved in developing REMS, the FDA has met with health care profession als, patientadvocacy groups, and representatives from the pharma ceutical industry. A public meet ing on this topic was held in May 2009. Discussions have focused on ways to curb abuse and acci dental harm while not limiting access for treatment of pain.
Meanwhile, the FDA will con tinue to take steps to manage the risks associated with new and ex isting products. For example, on July 16, 2009, the FDA approved Onsolis (BioDelivery Sciences), a fentanyl buccal soluble film used for the management of break through pain in patients 18 years of age or older who have cancer and are already using another opi oid. Given the significant risk posed by Onsolis if taken by some one who is not opioidtolerant, the agency called for the institution of a REMS called the Full Ongo ing Commitment to User Safety, or FOCUS, program to manage these risks and to reduce the like lihood of misuse and abuse.
In January 2009, the FDA con vened an advisory committee meeting to discuss the safety and continued marketing of propoxy phene products. Propoxyphene, a lowpotency opioid indicated for mildtomoderate pain, has been on the U.S. market since 1957. A number of questions had surfaced regarding the safety and useful ness of propoxyphene in today's armamentarium. In July 2009, the FDA made public its decision to require the makers of propoxy phenecontaining products to make changes in safety labeling, includ ing adding a boxed warning and a medication guide to address the risks of overdose, both acciden tal and intentional. The agency is initiating additional studies of propoxyphene safety.
Although the risks of serious or fatal gastrointestinal bleeding from nonsteroidal antiinflamma tory drugs (NSAIDs) have long been recognized, additional safety concerns have also emerged about these agents. In April 2005, the FDA implemented the recommen dation of an advisory committee to require a boxed warning on the labels of NSAIDs (except aspirin) about the risk of excess myocar dial ischemia, particularly in pa tients with preexisting heart disease.
Despite increased awareness of the harm resulting from the use of NSAIDs, acetaminophen, opi oids, and other drugs for pain, it is likely that extensive prescrib ing and use of these drugs will continue. Given this reality, there is a need for more vigorous risk management efforts by the FDA and other stakeholders in the health care system. The FDA can not address these risks on its own; prescribers and users of analgesics must also participate in this effort. Any riskmanage ment option must be considered in the light of its potential effect on the use of other analgesics, given that most analgesic drugs have substantial liabilities. The unintended consequences of shift ing use from one drug class to another, for example, must be considered carefully. The FDA has been implement ing strategies to reduce prevent able harm from suboptimal use, misuse, and abuse of analgesics. Although these strategies are in tended to ensure that risks are better managed, their effective ness in reducing harm will require ongoing evaluation. For products that requiring REMS, metrics and procedures for tracking outcomes and the effectiveness of the in terventions must be identified. The FDAAA requires each REMS to contain a timetable for its as sessment that is unique to that drug. If risks are not adequately mitigated, then additional steps can be taken.
Although management of the risks posed by the current arma mentarium will be a predominant theme for the foreseeable future, the FDA is also exploring ways to improve analgesicdrug devel opment, primarily through re search into better designs for pain trials, in the hope that high ly effective drugs with more easily managed risks may be developed.
No potential conflict of interest relevant to this article was reported. The drugs reported to be involved in these episodes include codeine, hydrocodone, hydromorphone, meperidine, morphine, opium, oxycodone, pentazocine, propoxyphene, tramadol, and other drugs with morphinelike effects. Nonprescription methadone is not included. Data are from the Treatment Episode Data Set, 1997 through 2007.
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N o issue has dominated the health care reform debate as much as whether the U.S. gov ernment should offer a health insurance plan to compete with private insurers -the socalled public option. Congress has dis cussed two approaches to the public option, one of which would have the public plan pay provid ers at rates close to Medicare rates (generally, substantially below those of private insurers). Oppo sition by insurers, providers, and the business community, as well as fears that such a payment structure would lead to a single payer system, has pushed this "robust" public option off the table. Instead, both the House bill and, presumably, a final Sen
